Incyte
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for ...
Latest News
8 hours ago · reuters.com
Incyte says EU approves oral treatment for chronic skin diseaseIncyte says EU approves oral treatment for chronic skin disease
8 hours ago · businesswire.com
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis SuppurativaWILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
5 days ago · marketbeat.com
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.
6 days ago · seekingalpha.com
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference TranscriptIncyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
11 days ago · businesswire.com
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research InstituteWILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.
18 days ago · benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For FridayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
18 days ago · seekingalpha.com
Incyte: Upgrading To Hold After ESMO Closed The Valuation GapI upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.
18 days ago · zacks.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
18 days ago · seekingalpha.com
Incyte Corporation (INCY) Q3 2026 Earnings Call TranscriptIncyte Corporation (INCY) Q3 2026 Earnings Call Transcript
18 days ago · marketbeat.com
What Incyte (INCY) Said on Its Q3 Earnings CallIncyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove INCY